|
Melanie S. Joy, Pharm.D., PhD, FCCP, FASN
|
|
Dr. Joy's research interests focus on the role of drug metabolism and transport on pharmacokinetic and pharmacodynamic alterations seen in various forms of kidney diseases. Dr. Joy recently completed a 5-year Mentored Patient-Oriented Research Career Development Award (K23) from the NIH to study pharmacokinetic and pharmacogenomic alterations in responses to therapies employed to treat ANCA Vasculitis, and completed a study funded by the American College of Clinical Pharmacy that proposed to elucidate pharmacogenomic reasons for poor response to therapies employed to treat lupus nephritis, and an NIH study to determine pharmacokinetics and pharmacodynamics for FSGS novel treatments. Recent publications describe some of the results from these studies. Dr. Joy's clinical interests include the application of pharmacology and drug disposition to the selection of rational drug treatment regimens for kidney diseases. Dr. Joy has been an Ad Hoc Reviewer to the NIH (NIDDK) and FDA (Cardiovascular and Renal Drugs), elected to the National Academies of Practice (NAP), and selected to the Chronic Kidney Disease Advisory Group of the American Society of Nephrology, National Kidney Disease Education Program Pharmacy Taskforce (NKDEP, NIH), and United States Pharmacopeia Expert Committee for Nephrology and Urology. Stanton ML, Joy MS, Frye RF. Improved method for determination of the drug transporter probe fexofenadine in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Dec 24. [Epub ahead of print] Melanie S. Joy, Reginald F. Frye, Kristi Stubbert, Kim R. Brouwer, Ronald J. Falk, MD, Evan D. Kharasch. Use of Enantiomeric Bupropion and Hydroxybupropion to Assess CYP2B6 Activity in Glomerular Kidney Diseases. J Clin Pharmacolo. 2010 Jan 26. [Epub ahead of print] Joy MS, Gipson DS, Dike M, Powell L, Thompson A, Vento S, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H. Phase I trial of adalimumab in FSGS: II. Report of the FONT study group. Am J Kidney Dis. 2009 Nov 20. [Epub ahead of print] Joy MS, Hilliard T, Hu Y, Hogan SL, Wang J, Falk RJ, Smith PC. Influence of clinical and demographic variables on mycophenolic acid pharmacokinetics in ANCA-associated vasculitis<. Annals of Pharmacotherapy 2009;Jun;43(6):1020-7. Epub 2009 Jun 2. Joy MS, Dornbrook-Lavender K, Blaisdell J, Hilliard T, Boyette T, Hu Y, Hogan SL, Candiani C, Falk RJ, Goldstein JA. CYP2C9 allelic variants and differential pharmacodynamic responses to losartan in patients with chronic kidney disease and proteinuria.. European Journal of Clinical Pharmacology 2009;65(9):947-53. Joy MS, Hilliard T, Hogan SL, Dooley MA, Falk RJ, Smith PC. Pharmacokinetics of mycophenolic acid in patients with lupus nephritis. Pharmacotherapy 2009;29(1):7-16. Joy MS, Gipson DS, Dike M, Powell L, Thompson A, Vento S, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H. Rosiglitazone and N-desmethylrosiglitazone pharmacokinetic are altered in patients with focal segmental glomerulosclerosis (FSGS): I. Report of the novel therapies for resistant FSGS (FONT) study group. CJASN 2009;4(1):39-47. Joy MS, Hogan SL, Thompson BD, Finn WF, Nickeleit V. Cytochrome P450 3A5 expression in the kidneys may modulate calcineurin inhibitor nephrotoxicity. Nephrology, Dialysis, Transplantion March 2007 [Epub ahead of print] Joy MS, Nickeleit V, Hogan SL, Thompson BD, Finn WF. Renal expression of P-glycoprotein and nephrotoxicity secondary to calcineurin inhibitors. Pharmacotherapy 2005; 25(6): 779-89.
|
|
